Rome, Italy - October 24, 2024 - ArcticZymes Technologies ASA (OSE: AZT), a
global leader in enzyme innovation for bioprocessing, is excited to unveil
breakthrough developments presented at the prestigious European Society of Gene
and Cell Therapy (ESGCT) 2024 conference.

The annual ESGCT conference is renowned for spotlighting breakthrough
innovations in gene and cell therapy. It acts as a global stage for companies to
showcase the latest scientific and technological achievements impacting their
work in the biotherapeutics industry.

In this context, ArcticZymes salt active nucleases featured in multiple ESGCT
presentations, underscoring its critical role in advancing gene therapy
innovation. This includes the Austrian Centre of Industrial Biotechnology
(acib), an internationally recognized non-profit research centre.

ACIB's presentation compared ArcticZymes' M-SAN HQ with Benzonase and
demonstrated M-SAN HQ's superior ability to break down not just loose DNA but
also chromatin (complex DNA structures). This results in a cleaner purification
process, producing purer and more effective virus-like particles (VLPs) used in
applications such as vaccines. In short, M-SAN HQ optimizes the removal of
unwanted materials, making the manufacturing process more efficient. This
achievement highlights the ongoing impact of ArcticZymes' enzymes in solving
complex bioprocessing challenges and showcases the value of its collaboration
with the Austrian Centre of Industrial Biotechnology in optimizing viral vector
production.

As a scientific conference first, to our knowledge, ArcticZymes enabled a live
AI-based Q&A for this presentation further demonstrating innovation to ESGCT
visitors (link to Q&A below).

Another presentation, by Oxford Biomedica (OXB), highlights M-SAN's role in
enhancing downstream recovery, reducing DNA contamination, and minimizing vector
aggregation, resulting in cleaner, higher-quality lentiviral vectors. By
degrading chromatin and optimizing DNA clearance at physiological salt levels, M
-SAN simplifies workflows and boosts efficiency, which is crucial for regulatory
compliance.

A few quotes from this presentation include:

"M-SAN demonstrated superior performance compared to the Industry Standard
Nuclease when integrated into OXB's LV production process", and "SAN also
outperformed the Industry Standard Nuclease when integrated into OXB's LV
production" and "Over 10-fold reduction in residual DNA compared to the Industry
Standard Nuclease"

The OXB presentation focus on salt active nucleases serves to reaffirm their
importance for improving process efficiency and product quality, both of which
contribute to economic gains for them and their customers in the highly
competitive landscape of gene therapy.

"Collaborations with leading institutes like ACIB continue to push the
boundaries of what is possible in bioprocessing," said ArcticZymes CEO Michael
Akoh. "The exceptional interest around our booth at ESGCT 2024 reaffirms the
strong interest in ArcticZymes' solutions, as attendees recognized the tangible
benefits our enzymes bring to improving efficiency and product quality in viral
vector production.

More information about ArcticZymes at ESGCT at https://tinyurl.com/AZesgct2024

For more information, please contact:

ArcticZymes Technologies ASA
CEO, Michael B. Akoh          Tel: +46 (0) 70 262 37 15
                                    ir@arcticzymes.com

About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on the
development, manufacturing and commercialization of novel recombinant enzymes
for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing.

Listed on the Oslo Stock Exchange since 2005 originally under the [AZT] ticker.
Its headquarters are based in Tromsø, Norway, at the SIVA Innovation Centre.

ArcticZymes Technologies' IP and capabilities are protected via a large
portfolio of patents.

For more information, please visit the website: www.arcticzymes.com